Overview of Infliximab BS

Property	Description
Active ingredient	Infliximab
Form	Lyophilized powder for intravenous infusion
Pharmacological class	Immunosuppressive agent; TNF-α inhibitor
General purpose	Modulates the immune response to reduce systemic inflammation
Origin	Biologically synthesized (recombinant DNA technology)

Infliximab BS is a biosimilar version of the biologic medicine Infliximab, classified as an immunosuppressive agent and a Tumor Necrosis Factor alpha (TNF-α) inhibitor. It is a targeted therapy used to manage chronic, systemic inflammation driven by an overactive immune system, an approach recognized for providing sustained disease control.

Defining Infliximab BS: A Targeted Biological Immunosuppressant

Infliximab BS is a highly specific biological product belonging to the class of Disease-Modifying Antirheumatic Drugs (DMARDs). This type of drug is produced in living systems using complex biotechnology, contrasting sharply with chemically synthesized small-molecule medicines. As a biosimilar (BS), the medication is demonstrated to be highly similar to, and to have no clinically meaningful differences from, the original reference Infliximab product in terms of safety and potency. The biosimilar development process is designed to ensure that Infliximab BS products achieve equivalent clinical efficacy to the reference product.

Composition and Origin: The Infliximab Monoclonal Antibody

The single active ingredient is Infliximab, which is a specialized protein known as a chimeric monoclonal antibody. The unique chimeric structure, combining components derived from both human and murine (mouse) sources, is a differentiating factor in its molecular design among biologics. This large, complex molecule is manufactured through advanced recombinant DNA technology using cultured cell lines. Infliximab BS is provided as a sterile lyophilized powder in a vial, designed to be reconstituted into an aqueous solution for eventual intravenous administration.

General Therapeutic Purpose: Neutralizing Tumor Necrosis Factor alpha (TNF-α)

The primary therapeutic purpose of this drug is to reduce chronic, destructive inflammation by acting as a highly selective Anti-TNF-α therapy. The drug achieves this by binding directly to the Tumor Necrosis Factor alpha (TNF-α) protein, a potent signaling molecule that plays a central role in driving the inflammatory cascade. By binding and neutralizing TNF-α throughout the body, Infliximab BS helps to modulate the body's exaggerated immune response, thereby minimizing the tissue damage caused by systemic inflammation.

Regulatory References

Infliximab (Remicade) in Inflammatory Diseases

What side effects are possible with Infliximab BS?

Possible Side Effects and Safety Information

The safety profile of Infliximab, a Tumor Necrosis Factor alpha (TNF- alpha) inhibitor, is officially documented by regulatory agencies and is primarily defined by risks related to its immunosuppressive action. Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOC).

Frequency-Classified Adverse Reactions

Adverse reactions are officially reported using the following frequency categories:

Classification	Examples (as per regulatory labels)
Very Common (ge 1/10)	Upper respiratory tract infection, headache.
Common (ge 1/100 to < 1/10)	Infusion-related reactions, bacterial infections, nausea, rash, fatigue.
Uncommon (ge 1/1,000 to < 1/100)	Serum sickness, heart failure, anemia.
Rare (ge 1/10,000 to < 1/1,000)	Sepsis, tuberculosis, demyelinating disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights serious adverse reactions, notably the risk of severe infections (including opportunistic infections and reactivation of latent infections like Tuberculosis). Serious but rare events also include certain malignancies (such as lymphoma), severe hepatic events, and new onset or worsening of heart failure.

Time-related patterns specify that infusion-related reactions are most frequent during or shortly after administration, while delayed hypersensitivity reactions may occur three to twelve days later. The drug is formally contraindicated in patients with a history of hypersensitivity to its components or with moderate to severe heart failure. Safety considerations for specific populations include a higher observed incidence of serious infections in older adults and a documented increased risk of malignancies in pediatric patients.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Infliximab BS is primarily defined by the increased incidence of dose-dependent adverse reactions observed at exposure levels significantly higher than recommended, such as those reaching up to 20 mg/kg in clinical studies. No unique acute overdose syndrome is specifically documented for this medication. Manifestations of extreme exposure may involve the cardiovascular system and other systemic effects, potentially presenting signs like hypotension (low blood pressure), dyspnea (shortness of breath), angina, and dizziness.

The regulatory documents define the overdose situation by emphasizing the mandated emergency response. If an overdosage is suspected or confirmed, patients or caregivers must seek immediate medical attention or contact a Poison Control center. Urgent assistance is required for any known or suspected excessive dosing. Because no specific antidote is known for this monoclonal antibody, the treatment approach is strictly limited to symptomatic and supportive measures.

Furthermore, close monitoring in a clinical setting is required for an extended period due to the drug's prolonged systemic half-life. The regulatory information does not explicitly detail specific overdose severity information for pediatric, hepatic, or renal populations.

Therapeutic Uses of Infliximab BS

Therapeutic Focus: Symptom Management and Functional Support

Infliximab biosimilar (BS) is commonly used to manage several chronic, debilitating autoimmune conditions that involve inflammation and physical discomfort. The primary therapeutic focus is to help manage symptoms and support patients struggling with heightened discomfort and functional strain. It is applied across domains where additional symptomatic support is needed.

This medicine is commonly used for a range of conditions, primarily to help with the reduction of signs and symptoms, and to assist with maintaining symptomatic stability. This includes use in conditions presenting with systemic or localized discomfort, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and chronic severe plaque psoriasis.

The treatment is utilized when symptoms create noticeable interference with daily stability, serving as supportive relief when symptoms become more noticeable. The medication provides support that helps ease the overall symptom burden.

Quick Fact: Assists with Functional Strain

Easing Digestive Discomfort and Interference

This domain covers use in conditions like Crohn's disease and ulcerative colitis. Infliximab BS helps address symptom clusters that interfere with daily comfort, such as chronic pain and diarrhea. Its role is relevant for managing disease activity and may assist with maintaining symptomatic control.

Managing Joint Pain and Mobility Strain

This therapeutic domain includes conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is applied when symptoms create noticeable functional strain, such as joint swelling and stiffness. The treatment assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

Calming Chronic Skin Symptoms

This block covers the management of chronic severe plaque psoriasis. It is used in situations involving distressing symptoms that may become intense or disruptive, such as extensive skin lesions. Infliximab BS contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

The eligibility for using Infliximab BS is strictly defined by regulatory bodies, establishing clear rules for approved populations and those who must not use the medicine.

Contraindications and Restrictions

Classification	Rule (Official Regulatory Wording)
Absolute Contraindication	Patients with a known severe hypersensitivity to infliximab, murine proteins, or excipients.
	Patients with severe active infections (e.g., active TB, sepsis) or moderate to severe heart failure (NYHA class III/IV).
Conditional Use Only	Patients with latent tuberculosis must receive treatment prior to therapy. Patients with mild heart failure (NYHA class I/II) require close monitoring.

Age and Physiological Eligibility

Population Group	Eligibility Status
Adults	Eligible across all approved indications.
Pediatric Use	Approved for patients 6 years of age and older with Crohn's Disease and Ulcerative Colitis; safety is not established in children under 6 years.
Pregnancy/Lactation	Not recommended; use during pregnancy should only be considered if clearly necessary.

The official documents define eligibility based on age, cardiac status, and active infectious disease status. Furthermore, use is not recommended in patients with demyelinating disorders, and monitoring is required for carriers of the Hepatitis B Virus (HBV).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns of Infliximab, strictly based on government regulatory documentation.

Interactions with Immunomodulating Agents

Co-administration with specific biological therapeutics (such as Anakinra or Abatacept) is officially not recommended. This restriction is due to an increased risk of serious infections and the lack of demonstrated added clinical benefit, as noted in the prescribing information.

Conversely, co-administration with non-biological immunosuppressants, such as Methotrexate, Azathioprine, or 6-Mercaptopurine, has been associated with an alteration in the drug's exposure. The presence of these agents generally leads to higher trough concentrations of Infliximab and a reduced immunogenicity.

Interactions Affecting Other Medicines (Pharmacokinetic)

Infliximab's mechanism can lead to a change in the concentrations of other medicines. By inhibiting Tumor Necrosis Factor alpha (TNF- alpha), Infliximab may normalize the formation of certain Cytochrome P450 (CYP) enzymes previously suppressed by inflammation. This normalization can result in the reduced plasma concentration of co-administered CYP substrates that have a narrow therapeutic index, such as Warfarin or Phenytoin.

Interactions with Vaccines and Timing Rules

Concurrent administration of Live Vaccines or Therapeutic Infectious Agents is not recommended due to the risk of clinical infections resulting from additive immunosuppression. A specific timing-based restriction is in place for infants exposed in utero to Infliximab: a six-month waiting period following birth is recommended before the administration of any live vaccine.

Mechanism of Action

TNF- alpha Neutralization and Receptor Blockade

Infliximab BS acts as a highly selective antagonist by binding to the inflammatory signaling protein Tumor Necrosis Factor alpha (TNF- alpha) in both its circulating (soluble) and cell-surface (transmembrane) forms. This neutralization step prevents the cytokine from engaging its receptors ( TNFR1 and TNFR2), thereby preventing the propagation of the initial molecular signal.

Elimination of Inflammatory Cell Sources

The mechanism goes beyond simple blockade; binding to the transmembrane TNF- alpha expressed on activated immune cells (e.g., macrophages) triggers cytotoxic actions, including apoptosis and complement-mediated lysis. This targeted mechanism contributes to the functional clearance of TNF- alpha-expressing cells, resulting in a reduction of the local inflammatory cell population.

Pathway Suppression and Tissue Protection

By blocking TNF- alpha signaling, the drug inhibits major downstream intracellular cascades, such as the NF- kappaB and MAPK pathways. This functional suppression leads to a widespread downregulation of secondary inflammatory mediators and limits the recruitment of new immune cells. The restriction of destructive enzyme release (e.g., Matrix Metalloproteinases) is a direct functional consequence of this pathway suppression.

Dosage and Administration Information

How Infliximab BS is Used: Official Administration Guidelines

Infliximab BS (biosimilar) is administered only under the direct supervision of a healthcare professional in a clinical setting, such as a hospital or specialized infusion clinic. Its use follows a precise, standardized schedule.

Administration and Dosing Schedule

Instruction	Detail
Route of Administration	Intravenous (IV) infusion only.
Standard Dosing	The dose is calculated based on patient body weight (e.g., 5 mg/kg for most indications).
Induction Phase	The initial three doses are given at Week 0, Week 2, and Week 6.
Maintenance Phase	Following the initial induction, maintenance doses are typically administered every 8 weeks.

Preparation and Procedural Rules

Infliximab BS, supplied as a lyophilized powder, requires strict preparation before use:

Reconstitution and Dilution: The powder must be reconstituted and then diluted using 0.9% Sodium Chloride Injection (saline) to a specific volume for the infusion.
Infusion Duration: The diluted solution must be infused intravenously over a period of no less than two hours (120 minutes).
Special Conditions: The infusion requires the use of an in-line, low-protein-binding filter, and the solution must not be mixed with other medications in the same intravenous line.

Population and Timing

For approved pediatric indications (e.g., Crohn's Disease, Ulcerative Colitis), the standard 5 mg/kg dose is used. No specific dose adjustment is generally required for older adults. If a scheduled dose is missed, the recommendation is to administer it as soon as possible and then resuming the subsequent schedule every 8 weeks from that date.

These official instructions define the required two-phase, cyclic protocol for this medicine, ensuring a standardized, controlled approach to its long-term administration.

Recent Clinical Evidence

Infliximab BS: Recent Clinical Evidence

The research base for Infliximab biosimilar (BS) is founded on comparative studies designed to demonstrate structural and functional similarity to the reference infliximab product. This evidence highlights what is known and what is still uncertain.

Comparative Studies and Extrapolation

For Rheumatoid Arthritis (RA), the most extensive evidence comes from head-to-head Randomized Controlled Trials (RCTs). These studies were designed to observe whether measured outcomes in the biosimilar group remained within the pre-defined regulatory range of similarity to the reference product among adults with active RA. This research examined symptom and disease activity patterns.

For other approved conditions, including Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn's Disease (CD), Ulcerative Colitis (UC), and chronic severe plaque psoriasis, the primary basis for regulatory acceptance is scientific extrapolation. This principle relies on the established similarity of the drug's fundamental activity and structure, meaning dedicated large-scale RCTs are not required for every condition.

Real-World Data and Limitations

Research specifically examining the biosimilar in these conditions often consists of observational cohort studies and real-world evidence (RWE). These studies explore outcomes related to disease activity and patient-reported discomfort, particularly following a transition from the reference product.

The durability of findings is explored through extension studies of the initial RCTs, which monitored patients for intermediate periods (up to one or two years). While these studies reported patterns of treatment persistence, limited information for long-term outcomes is available over several years. Data for specific patient groups, such as pediatric populations and older adults with comorbidities, remain insufficient, and results apply primarily to the populations studied in the main trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Infliximab BS (FAQ)

Q: What happens if I miss an infusion of Infliximab BS?

Regulatory guidance advises administering a missed dose as soon as possible. Following the administration of the missed dose, resuming the subsequent schedule is advised to maintain the planned treatment pattern.

Q: Can I still get the flu shot or other vaccines while on Infliximab BS?

Official product information states that live vaccines or therapeutic infectious agents should not be given during treatment. However, patients are generally advised in the label to be up to date with all recommended non-live vaccines prior to initiating therapy. Guidance on any vaccination during treatment relies on the specific advice of a prescribing healthcare professional.

Q: Is it safe to drink alcohol while I am receiving Infliximab BS?

There are no known direct drug interactions between Infliximab and alcohol listed on the regulatory label. However, official safety information notes that the drug carries a warning for potential hepatotoxicity (liver damage). Excessive alcohol consumption may increase the risk of this side effect, and this noted risk is a factor described in relation to the drug's safety profile.

Q: How does Infliximab BS impact fertility or pregnancy?

The drug is known to cross the placenta, primarily in the second and third trimesters of pregnancy. Official guidance states that use during pregnancy is recommended only if the benefits clearly outweigh the potential risks. Specific information detailing the effects on fertility (the ability to conceive) for either men or women is not explicitly provided in the core regulatory label.

Q: Is it normal to have a reaction during the infusion?

Infusion-related reactions are listed as a common side effect in the regulatory documentation, meaning they occur in 1% to 10% of patients. These can happen during or shortly after the administration of the medicine. These reactions range from mild symptoms to more serious hypersensitivity events.

Q: Is Infliximab BS the same as Remicade or Inflectra?

Infliximab BS is a biosimilar product. This means it has been rigorously studied and proven to be highly similar to the original reference product, Remicade, with no clinically meaningful differences in terms of safety and effectiveness. Inflectra is also a biosimilar version of Remicade.

Q: How long can a person stay on Infliximab BS treatment?

Infliximab BS is designed to be a long-term therapy. Treatment involves a maintenance phase where infusions are typically administered every eight weeks. While clinical studies include monitoring patients for intermediate periods, regulatory research explicitly states that evidence for long-term outcomes spanning many years remains limited.

Q: How quickly does Infliximab BS start to work?

According to official clinical trial data for conditions such as Ulcerative Colitis and Crohn's Disease, the first signs of clinical response and remission for many patients can be observed as early as Week 8 of therapy. The timeline for initial improvement can vary based on the patient and the condition being treated.

Q: Can Infliximab BS affect my immune system?

Yes. Infliximab BS belongs to a class of medicines known as immunosuppressive agents. The drug works by blocking the activity of the immune protein TNF-alpha, which plays a central role in inflammation. This action results in a reduced immune response and carries an associated risk of serious infections, as noted in the Boxed Warning.

Q: Is there a link between Infliximab BS and cancer risk?

Official labeling includes a Boxed Warning regarding the risk of malignancy (cancer). This includes rare reports of lymphomas in children and adolescents, and a rare but aggressive form of cancer, Hepatosplenic T-cell Lymphoma, reported primarily in young adult males with inflammatory bowel disease.

Q: What should I do if I feel sick after an Infliximab BS treatment?

Regulatory safety information describes conditions where immediate medical evaluation is necessary, such as signs of a serious infection (like fever, persistent cough, or flu-like symptoms) or a severe hypersensitivity reaction. This is based on the official adverse event warnings.

Q: Can Infliximab BS be used to treat uveitis or other eye issues?

The drug is not formally approved by regulatory agencies for the treatment of uveitis or other eye conditions. Its approved indications are strictly limited to Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and chronic severe Plaque Psoriasis.

Q: Does Infliximab BS treatment require other medications, like steroids?

For the treatment of Rheumatoid Arthritis specifically, the medicine is indicated for use in combination with methotrexate. For other approved conditions, it can be used alone or with other non-biologic immunosuppressants. This depends on the specific condition being treated, as defined in official prescribing information.

Q: Do I need blood tests before every Infliximab BS infusion?

Regulatory labeling mandates testing for latent tuberculosis and Hepatitis B Virus (HBV) prior to starting therapy. While close clinical monitoring is required throughout treatment, there is no blanket requirement in the label for routine blood tests before every infusion.

Q: What is the chance of having a serious allergic reaction to Infliximab BS?

The frequency of serious allergic reactions, or hypersensitivity, is classified in the official safety documents. Specific events like serum sickness are classified as Uncommon (occurring in 1 in 100 to 1 in 1,000 patients), while other serious reactions are classified as Rare.

Q: Does taking Infliximab BS make me more sensitive to the sun?

Official safety information includes warnings related to sun exposure due to a potential increased risk of skin reactions. Additionally, there is an association with a rare, but potential, risk of developing certain skin cancers.

Q: How do doctors monitor treatment with Infliximab BS?

Monitoring focuses on checking for signs of infection (like TB or HBV reactivation), monitoring for new or worsening heart failure symptoms, and checking for changes in liver enzymes. Therapeutic Drug Monitoring (TDM) may be used to measure drug levels if a patient is losing response to the drug.

Q: What are the main goals of treatment with Infliximab BS?

The official goals of treatment listed in the product label include reducing disease signs and symptoms and working to induce and maintain clinical remission. For conditions like Rheumatoid Arthritis, the goals also include inhibiting the progression of structural joint damage.

Q: Is there evidence for using Infliximab BS in children with juvenile idiopathic arthritis?

The currently approved pediatric indications for Infliximab BS are limited to Crohn's Disease and Ulcerative Colitis in patients 6 years of age and older. Juvenile Idiopathic Arthritis is not an approved use listed on the core regulatory label.

Q: What is the risk of developing antibodies to Infliximab BS?

As with any biologic medicine, there is a risk of developing antibodies against the drug, which is an expected immune response. The development of these antibodies has been associated with a greater risk of infusion reactions and a potential reduction in the duration of the drug's effect.

Q: What are the long-term effects of taking Infliximab BS?

While the medicine is designed for continuous, long-term maintenance use, regulatory research explicitly states that evidence specifically detailing long-term outcomes spanning several years remains limited. The available long-term data primarily applies to the patient populations studied in the main clinical trials.

How should Infliximab BS be stored and disposed of?

Storage and Disposal of Infliximab Biosimilars

Unopened Vial Storage Conditions

Unopened vials of Infliximab biosimilars must be stored under refrigeration at 2 C to 8 C (36 F to 46 F). Vials must be kept in the original carton to protect the powder from light. It is a mandatory requirement that the product not be frozen.

Alternative Storage: An unopened vial may be stored once for up to six months at room temperature, not exceeding 30 C (86 F). Once removed from refrigeration for this purpose, the vial cannot be returned to the refrigerator.

Disposal Requirements

Infliximab biosimilars are preservative-free. Any unused portion of the reconstituted or diluted solution must be discarded immediately after use. All expired or unused product must be disposed of according to local pharmaceutical waste requirements.

Infliximab BS